Mammogen, a US-based developer of RNA-powered molecular diagnostics for women's health, has raised up to $30 million in Series A funding led by an undisclosed leading U.S. public retirement system. The company's lead product is genTRU-breast, a blood-based cfRNA assay designed to support earlier breast cancer detection alongside imaging, especially for women with dense breast tissue. The capital will advance a prospective clinical validation trial and move the assay toward CLIA commercialization.
Density Notification Rules Drive Demand
The timing aligns with new federal MQSA breast density notification requirements that increase the need for supplemental screening tools. Mammogen's blood test is positioned to integrate directly into existing imaging workflows rather than replace them. This approach targets a gap where traditional mammography has visibility limitations.
Dense Tissue Limits Mammography Accuracy
Approximately 38 million women in the US have dense breast tissue, which can mask cancers on standard mammograms and elevates risk. Current screening pathways leave many patients with uncertain results, prompting demand for non-invasive molecular options that capture active biology through cfRNA signals instead of relying solely on tumor shedding detected by cfDNA methods.
RNA Platform Complements Imaging Workflows
Mammogen's genTRU-breast assay uses qPCR infrastructure for scalable deployment and reports 99% sensitivity for Stage I breast cancer in internal validation. Unlike tissue-based genomic tests from competitors such as Agendia or Veracyte that focus on post-diagnosis recurrence risk, the assay is designed as a pre-diagnostic blood draw that fits alongside imaging.
As CEO Elizabeth Cormier-May stated:
"Mammogen was founded on the conviction that women deserve access to diagnostics that detect disease earlier."
The platform is built to expand into additional women's health applications beyond breast cancer.
Public Pension Fund Signals Long-Term Validation
The lead investor is a major U.S. public retirement system with a focus on healthcare technologies that deliver societal impact. This institutional backing, rather than traditional venture capital, provides credibility for a pre-commercial diagnostics company and supports milestone-based advancement of clinical programs.
Breast Cancer Diagnostics Market Expands
The breast cancer diagnostics market stands at $5.86 billion in 2025 and is projected to reach $11.36 billion by 2033 at an 8.8% CAGR, according to Grand View Research. Broader liquid biopsy markets are also attracting capital amid regulatory tailwinds and a shift toward RNA-based early detection approaches. Mammogen differentiates by targeting the pre-diagnostic screening segment for dense-breast populations rather than post-diagnosis treatment guidance.
Board Appointment Strengthens Governance
In June 2025, Mammogen appointed Denise "DeeDee" DeMan, a life sciences executive with more than 50 years of experience, as Chairwoman of the Board. Her involvement adds governance depth as the company advances clinical and commercial milestones.